36 results on '"Krueger, James G."'
Search Results
2. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
3. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation
4. A systematic review and critical appraisal of pharmacological treatments for pediatric hidradenitis suppurativa
5. Proteomic characterization of atopic dermatitis blood from infancy to adulthood
6. Secukinumab improves mild-to-moderate psoriasis: A randomized, placebo-controlled exploratory clinical trial
7. 33226 Analysis of histologic and molecular improvement in moderate-to-severe psoriasis: Results from a phase 1b trial of the novel allosteric Tyk2 inhibitor NTX-973
8. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement
9. The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris
10. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
11. 50378 Clinical efficacy of TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, is associated with modulation of disease and TYK2 pathway biomarkers in patients with moderate-to-severe psoriasis.
12. 52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials.
13. 52676 Safety and efficacy over one year of spesolimab treatment in patients with hidradenitis suppurativa (HS): Interim analysis of an open-label extension (OLE) study.
14. 43272 Differentiation of Therapeutic Monoclonal Antibodies Targeting IL-23 for the Treatment of Psoriatic Disease
15. 43019 Spesolimab for hidradenitis suppurativa: A proof-of-concept study
16. 15354 Response to treatment with secukinumab in obese patients with moderate to severe psoriasis
17. 14928 Epithelialized tracts are active mediators of inflammation in hidradenitis suppurativa
18. 17731 Evolving resolution of clinical, cellular, and transcriptomic inflammatory markers during 1-year IL-17A inhibition by secukinumab
19. 15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis
20. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study
21. Interleukins -23 and -17 in patients with palmoplantar pustular psoriasis and palmoplantar pustulosis: P7001
22. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients
23. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data
24. The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature
25. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
26. The immunologic basis for the treatment of psoriasis with new biologic agents
27. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody
28. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study
29. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis
30. Two considerations for patients with psoriasis and their clinicians:: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?
31. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease
32. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti–interleukin 17A/F nanobody, in moderate-to-severe psoriasis
33. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
34. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
35. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris
36. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: A clinical and pathologic study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.